Doug W. Email & Phone Number

Chicago, IL, US

Cambridge, MA, US

San Diego, California, US

Member of Compensation, Audit, Nomination and Corporate Governance committees.

Dublin, IE

• Executive officer of small biotech based in St Louis, MO and headquartered in Dublin, Ireland reporting directly to CEO. Led R&D team, interacted regularly and directly with board of directors, external analysts and.
• Developed post-launch development and evidence strategy for once at bed time sodium oxybate
• Designed post-launch build of R&D organization, transitioning from outsourced model
• Characterized future business development direction including target and archetype scenarios

Valby, Copenhagen, DK

• Guided U.S. R&D organization. Managed $60 million budget and 110 employees via ten direct reports. Oversaw cross-functional teams in clinical development and operations, medical affairs, value evidence (health.
• Drove transformation of U.S. and Canada R&D organizations, gaining influence on global pipeline and product portfolio. Orchestrated multi-year effort, building stronger cross-functional collaboration, tighter.
• Co-managed COVID task force in setting U.S. policy on remote working and mandatory precautions. Led group with polarized opinions and political perspectives on pandemic toward policy decisions to not only keep.
• Launched “Discovery University,” providing L&D that received 90% positive feedback. Established content committee of employees to create “curriculum,” including core track comprised of review of progress toward vision.

Durham, North Carolina, US

• Led therapeutic area leadership team. Managed direct reports to include TA heads in psychiatry, neurology, oncology, immunology, rheumatology, infectious disease, and pulmonology. Named functional head of medical.
• Spearheaded development and implementation of companywide technical competency map and career path for MDs.
• Led implementation of process to ensure client projects were fully supported by appropriate medical expertise. Developed efficiencies, freeing up TA leads while minimizing non-billable work time.
• Developed and instituted standardized therapeutic area strategies to focus new business acquisition toward specific countries, disease states, drug targets, trial methodologies, biomarkers, and sponsor companies.
• Cultivated greater communication and partnership between medical function, business development, and operational teams.

Durham, North Carolina, US

• Reviewed and provided strategic and scientific consultation on 75-plus CNS projects and protocols in Phases I to IV in schizophrenia, depression, substance abuse, Alzheimer’s disease, and other ailments.
• Acting as therapeutic expert in successful new business acquisition.
• Providing consulting services in CNS clinical development to a range of new clients.

Indianapolis, Indiana, US

Guided team of six MDs responsible for early clinical development strategy for all novel molecules in psychiatry, pain, and neurodegeneration portfolio from Phase Ib up to end of Phase II. Ensured collaboration with quantitative science, discovery research, non-clinical pharmacology, and drug disposition functions. Realigned early-phase medical team around.

Indianapolis, Indiana, US

Led development of Phase IIIb and IV medical planning process, and other projects.

Indianapolis, Indiana, US

Oversaw large medical affairs team, including five physicians and three scientists. Leveraged deep commercialization experience and drove greater medical-marketing collaboration and high volume of scientific output. Facilitated turnaround of flat Cymbalta sales into multibillion-dollar brand. Led medical marketing alignment by merging medical and brand.

Indianapolis, Indiana, US

Served as lead medical affairs physician for Zyprexa in U.S. market. Led unprecedented medical-marketing alignment within U.S. organization. Drove meaningful change in internal medico-legal-regulatory review processes. Influenced brand strategy for Symbyax and Zyprexa.

Indianapolis, Indiana, US

Guided and executed Phase III plan for successful approvals of bipolar maintenance for Zyprexa.

Indianapolis, Indiana, US

Led initial clinical development strategy for novel molecule in depression and anxiety.

Indianapolis, Indiana, US

Built team, and led and implemented Phase Three plans for successful approvals for bipolar depression and treatment-resistant depression.

Indianapolis, Indiana, US

Achieved “no significant findings” in just six months after previous GCP audit identified significant problems threatening to suspend organization from conducting trials. Pulled together team of brightest and best of each therapeutic area and worked with QA to focus on reinspection. Revised SOPs and trained employees.

Indianapolis, Indiana, US

CNS clinical development and medical affairs head for UK and Ireland affiliate. Built strong medical / commercial and thought leader relationships resulting in highly successful launch of Zyprexa.

Oxford, Oxfordshire, GB

Full time academic research position in Psychopharmacology Unit.

GB

Three year Royal College approved rotation in General Adult, Addiction, Old Age, Child and Adolescent and Forensic Psychiatry.

Mrcpsych, Psychiatry

Mbchb, Medicine